$3.25
15.11% today
Nasdaq, Apr 02, 08:49 pm CET
ISIN
US36322Q1076
Symbol
GLTO
Sector
Industry

Galecto Inc Stock price

$2.82
-1.19 29.68% 1M
-8.85 75.84% 6M
-1.83 39.35% YTD
-15.80 84.86% 1Y
-54.68 95.10% 3Y
-372.18 99.25% 5Y
-372.18 99.25% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.28 9.03%
ISIN
US36322Q1076
Symbol
GLTO
Sector
Industry

Key metrics

Market capitalization $3.73m
Enterprise Value $-9.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.48
P/B ratio (TTM) P/B ratio 0.26
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-16.90m
Free Cash Flow (TTM) Free Cash Flow $-18.62m
Cash position $14.18m
EPS (TTM) EPS $-18.59
Short interest 2.17%
Show more

Is Galecto Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Galecto Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Galecto Inc forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Galecto Inc forecast:

Buy
50%
Hold
50%

Financial data from Galecto Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.24 0.24
71% 71%
-
-0.24 -0.24
71% 71%
-
- Selling and Administrative Expenses 10 10
9% 9%
-
- Research and Development Expense 6.40 6.40
73% 73%
-
-17 -17
53% 53%
-
- Depreciation and Amortization 0.24 0.24
71% 71%
-
EBIT (Operating Income) EBIT -17 -17
54% 54%
-
Net Profit -21 -21
44% 44%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galecto Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galecto Inc Stock News

Neutral
GlobeNewsWire
14 days ago
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.
Neutral
GlobeNewsWire
about 2 months ago
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
5 months ago
-  Completed strategic review to focus on oncology and severe liver diseases -  Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines -  Appointed Dr. Amy Wechsler to the Board of Directors and Matthew Kronmiller as Executive Vice President of Strategy and Chief Business Officer BOSTON, Nov. 01, 2024 (GL...
More Galecto Inc News

Company Profile

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.

Head office United States
CEO Hans Schambye
Employees 5
Founded 2011
Website www.galecto.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today